Hyderabad, Feb 17 (TNT): Rx Propellant on Tuesday announced an investment of $100 million to develop a large-format, integrated life sciences campus in Genome Valley, reinforcing its long-term commitment to India’s research and development ecosystem.
The platform, established by Actis and par of General Atlantic, said the project will involve the development of over one million square feet of advanced laboratory infrastructure.
The campus will be delivered in phases over the next six years.
Planned as a single integrated campus with multiple blocks, the project is expected to be the largest life sciences campus in Genome Valley designed for corporations seeking to lease buildings supported by resilient, well-managed infrastructure.
The facility will cater to both Indian and global life sciences companies requiring scalable, high-quality infrastructure for R&D and allied operations. It will offer institutional-grade laboratory spaces, compliant buildings and high-performance electromechanical services.
Ashish Singh, CEO and Managing Director of Rx Propellant, said the investment reflects the company’s confidence in Hyderabad as a long-term anchor for global and domestic R&D. He noted that the company’s existing campuses in Genome Valley — 1GV and 3GV — are fully leased and host several leading global and Indian life sciences companies.
Beyond Hyderabad, Rx Propellant is also developing the Navi Mumbai Research District (NMRD) spread over 16 acres, planned as Mumbai’s largest cohesive ecosystem for science and research.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said the expansion underscores growing global interest in research, development and manufacturing partnerships in India and highlights Hyderabad’s emergence as a leading R&D hub.
The upcoming campus is expected to further strengthen Genome Valley’s position as a preferred destination for innovation-driven companies seeking globally benchmarked infrastructure solutions.
TNT TS
Leave a Reply